Development of 153Sm-bleomycin as a possible therapeutic complex

RADIOCHEMISTRY, RADIOPHARMACEUTICALS AND NUCLEAR MEDICINE

Development of ¹⁵³Sm-bleomycin as a possible therapeutic complex

BAHRAMI-SAMANI Ali，

GHANNADI-MARAGHEH Mohammad，

JALILIAN Amir Reza，

YOUSEFNIA Hassan，

MORADKHANI Sedigheh，

BOLOURINOVIN Fatemeh

Nuclear Science and Techniques

Vol.21, No.3

pp.165-170

Published in print 20 Jun 2010

DOI：10.13538/j.1001-8042/nst.21.165-170

46300

Due to interesting therapeutic properties of ¹⁵³Sm and antineoplastic antibiotic, bleomycin (BLM), ¹⁵³Sm-bleomycin (¹⁵³Sm-BLM) was developed as a possible therapeutic compound using ¹⁵³SmCl₃ and BLM. The ¹⁵³SmCl₃ was obtained by thermal neutron flux (5×10¹³ n·cm^–2·s^–1) of an enriched ¹⁵²Sm₂O₃ sample, dissolved in acidic media. Under optimized conditions (room temperature, 45 min, 0.1 mg bleomycin for 740–3700 MBq ¹⁵³SmCl₃) a radiochemical purity over 98 % was obtained shown by HPLC (Specific activity = 55 TBq/mM). The ¹⁵³SmCl₃ and ¹⁵³Sm-BLM were administered into wild-type rats up to 96 h followed by biodistribution. The SPECT imaging of labeled compound in wild-type rats was performed and significant image pattern was observed for a radiolabeled bleomycin compound. The ¹⁵³Sm-BLM is a potential therapeutic compound and our experiments on this compound have shown satisfactory quality, and stability suitable for future therapeutic studies.

BleomycinSm-153BiodistributionRadiolabeling

References

[1]

Zhao G, Li F, Lin H, Lin H. Bioorg Med Chem, 2007, 15: 533-40.

[2]

Heffeter P, Jakupec MA, Körner W. Biochem Pharmacol, 2007, 73: 1873-86.

[3]

Firestone R B, Shirley V S, Baglin C M, Zipkin, J. Table of isotopes, 8th edition (CDROM), Version 1.0. Wiley-Interscience, New York, 1996.

[4]

Misra S N, Gagnani M A, Shukla R S. Bioinorg Chem Appl, 2004, 2: 155-92.

[5]

Kostova I. Curr Med Chem Anticancer Agents, 2005, 5: 591-602. Review.

[6]

Umezawa H T, Takeuchi S, Hori T J. Antibiot, 1972, 7:409-420.

[7]

Korppi-Tommola T, Huhmar H, Aronen HJ. Nucl Med Commun, 1999, 20: 145-152.

[8]

Jalilian A R, Yari Kamrani Y, Sadeghi M. Nukleonika, 2006, 51:119-123.

[9]

Jalilian A R, Shirazi B, Aboudzadeh R. Radiochim Acta, 2006, 94: 453-459.

[10]

Jalilian A R, Rowshanfarzad P, Sabet M. J Radioan Nucl Chem, 2005, 264: 617-621.

[11]

Ferro-Flores G, De Mara Ramrez F, Tendilla J I. Bio-conjugate Chem, 1999, 10: 726-734.

[12]

Jalilian A R, Fateh B, Ghergherehchi M. Nukleonika, 2005, 50: 143-148.

[13]

Jalilian A R, Zandi H, Sardari D. Nukleonika, 2009, 54(2) 135-141.

[14]

Melnyk D L, Horwitz S B, Peisach . J Inorganica Chimica Acta, 1987, 138: 75-78.

[15]

Anthoiine W E, Soiaiman D, Saryan L A. J Inorg Biochem, 1982, 11: 7544.

[16]

Bereman RD, Winkler ME. J Inorg Biochem, 1980, 13: 95-104.

[17]

Reynolds J E, Martindale, the extra pharmacopoeia, 31st edn.: London, Royal Pharmaceutical Society, 1996, 546-547.

[18]

Takita T, Umezawa Y, Saito SI. Tet Lett, 1982, 123: 521-524.

[19]

Welwyn H, Proceedings of First International Symposium on Bleomycin, London, Lundbeck Ltd. 1973, 1972-1974.

[20]

Jalilian A R, Mirzaii M, Karimian A. Iran J Nucl Med, 2005, 23:19-26.